Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: SDZNY )

43.37 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 43.37
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 43.37
Today's Range 43.37 - 43.37
52wk Range 25.71 - 43.65
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
Sandoz reports second-quarter sales and half-year 2024 results
From Sandoz Group
Via GlobeNewswire

Performance

YTD
+36.04%
+36.04%
1 Month
+12.71%
+12.71%
3 Month
+21.25%
+21.25%
6 Month
+34.56%
+34.56%
1 Year
+63.54%
+63.54%

More News

Read More
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
From Sandoz Group
Via GlobeNewswire
3 Spinoff Stocks You Should Buy Now: July 2024
Via InvestorPlace
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
From Sandoz Group
Via GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
From Sandoz Group
Via GlobeNewswire
Sandoz reports first quarter 2024 sales
From Sandoz Group
Via GlobeNewswire
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
From Sandoz Group
Via GlobeNewswire
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
From Sandoz Group
Via GlobeNewswire
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
From Sandoz Group
Via GlobeNewswire
Sandoz receives FDA approval for first and only denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Sandoz announces nominations to the Board of Directors and leadership change
From Sandoz Group
Via GlobeNewswire
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
From Sandoz Group
Via GlobeNewswire
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Via Benzinga
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
From Sandoz Group
Via GlobeNewswire
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Via Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Via Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.